Destiny Pharma plc
("Destiny Pharma" or "the Company")
Appointment of Nominated Adviser and Sole Broker
Brighton, United Kingdom - 22 January 2024 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life threatening infections, is pleased to announce the appointment of Shore Capital and Corporate Limited as its Nominated Adviser and Shore Capital Stockbrokers Limited as its Sole Broker with immediate effect.
- END -
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
pressoffice@destinypharma.com
Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
FTI Consulting (Financial PR)
Ben Atwell / Simon Conway / Michael Trace / Victoria Foster Mitchell
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
For further information on the company, please visit www.destinypharma.com
Existing Board - AIM Rule 17 Disclosures
The Group announces the following information is being disclosed pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies:
Sir Nigel Rudd - Chairman
Sir Nigel Rudd is a director of Loch Lomond Members Golf Club Limited. He was appointed on 29 November 2010; as such this was a current directorship at the date of the Company's announcement entitled "Appointment of new Chairman" dated 25 July 2023.
Christopher Tovey - Chief Executive Officer
Christopher Tovey was a former director of GW Pharma (Germany) GmbH and GW Pharma (France) SARL within 5 years of the date of the Company's announcement entitled "Board changes including appointment of new CEO" dated 19 July 2023.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.